Role of YES1 signaling in tumor therapy resistance

YES proto-oncogene 1(YES1)is an SRC family kinase(SFK)that plays a key role in cancer cell proliferation,adhesion,invasion,survival,and angiogenesis during tumorigenesis and tumor development.Reports suggest that YES1 amplification is associated with resistance to chemotherapeutic drugs and tyrosine kinase inhibitors(TKIs)in human malignancies.However,the mechanisms of drug resistance have not been fully elucidated.In this article,we review the literature on YES1 and discuss the implications of YES1 signaling for targeted therapy and chemotherapy resistance in malignancies.Moreover,recent advances in targeted therapy for YES1-amplified malignancies are summarized.Finally,we conclude that targeting YES1 may reverse drug resistance and serve as a valuable tumor treatment strategy.

Drag derived altitude aided navigation method

The navigation problem of the lifting reentry vehicles has attracted much research interest in the past decade. This paper researches the navigation in the blackout zone during the reentry phase of the aircraft, when the communication signals are attenuated and even interrupted by the blackout zone. However, when calculating altitude, a pure classic inertial navigation algorithm appears imprecise and divergent. In order to obtain a more precise aircraft altitude, this paper applies an integrated navigation method based on inertial navigation algorithms, which uses drag derived altitude to aid the inertial navigation during the blackout zone. This method can overcome the shortcomings of the inertial navigation system and improve the navigation accuracy. To further improve the navigation accuracy, the applicable condition and the main error factors, such as the atmospheric coefficient error and drag coefficient error are analyzed in detail. Then the damping circuit design of the navigation control system and the damping coefficients determination is introduced. The feasibility of the method is verified by the typical reentry trajectory simulation, and the influence of the iterative times on the accuracy is analyzed. Simulation results show that iterative three times achieves the best effect.

PD-L1 blockade by immune checkpoint inhibitors impairs sensitivity to osimertinib in EGFR-mutant non-small cell lung cancer cells

In recent years,the management of advanced nonsmall cell lung cancer(NSCLC)with epidermal growth factor receptor(EGFR)mutation has developed rapidly.Osimertinib is a third generation EGFR tyrosine kinase inhibitor(TKI),which has achieved satisfactory efficacy and tolerability as the first-line(FLARUA study[ref])and second-line(AURA series of studies[ref])treatment of patients with EGFRmutant NSCLC.This suggested that EGFR signaling is involved in the upregulation of programmed cell death ligand 1(PD-L1)expression,which induces apoptosis of T cells,thereby promoting immune escape of tumor cells[1].